Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis Delta

Hepatitis

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial

Lancet Gastroenterol Hepatol.

Asselah T, Lee SS, Yao BB, Nguyen T, Wong F, Mahomed A, Lim SG, Abergel A, Sasadeusz J, Gane E, Zadeikis N, Schnell G, Zhang Z, Porcalla A, Mensa FJ, Nguyen K

doi: 10.1016/S2468-

Hepatitis

Indication for treatment and severity of disease in treatment-naive patients with chronic hepatitis B virus infection

Eur J Gastroenterol Hepatol.

Post G, Shalev N, Baumgarten A, Shimakawa Y, Lemoine M, Krznaric I, Dupke S, Carganico A, Arastéh K, Ingiliz P

doi: 10.1097/MEG.

Hepatitis

Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection

Adv Ther.

Flamm SL, Kort J, Marx SE, Strezewski J, Dylla DE, Bacon B, Curry MP, Tsai N, Wick N

doi: 10.1007/s12325-020-01301-5.

HepatitisHepatology

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial

J Hepatol.

Brown RS Jr, Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, Horváth G, Zuckerman E, Carrion BR, Rodriguez-Perez F, Urbánek P, Abergel A, Cohen E, Lovell SS, Schnell G, Lin CW, Zha J, Wang S, Trinh R, Mensa FJ, Burroughs M, Felizarta F

doi: 10.1016/j.jhep.2019.10.020.

Hepatitis

Long-Term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients with Chronic HCV Infection

Clin Gastroenterol Hepatol.

Younossi ZM, Stepanova M, Racila A, Afendy A, Lawitz EJ, Schwabe C, Ruane PJ, Lalezari J, Reddy KR, Jacobson IM, Muir AJ, Gaggar A, Myers RP, Younossi I, Nader F

doi: 10.1016/j.cgh.2019.07.047.

HepatitisHepatology

Hepatitis flare-related decompensation is associated with better outcomes in patients with chronic hepatitis B

Clin Gastroenterol Hepatol.

Chang ML, Cheng JS, Chien RN, Liaw YF

doi: 10.1016/j.cgh.2020.01.018.

Hepatitis

Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic HBV Infection: Systematic Review and Meta-analysis

Clin Gastroenterol Hepatol.

Anderson RT, Choi HSJ, Lenz O, Peters MG, Janssen HLA, Mishra P, Donaldson E, Westman G, Buchholz S, Miller V, Hansen BE

doi: 10.1016/j.cgh.2020.05.041.

HepatitisHepatology

Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy

Gastroenterology.

Lok AS, Sulkowski MS, Kort JJ, Willner I, Reddy KR, Shiffman ML, Hassan MA, Pearlman BL, Hinestrosa F, Jacobson IM, Morelli G, Peter JA, Vainorius M, Michael LC, Fried MW, Wang GP, Lu W, Larsen L, Nelson DR

doi: 10.1053/j.gastro.2019.08.008.

Hepatitis

Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study

J Hepatol.

Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Rajender Reddy K, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MW

doi: 10.1016/j.jhep.2019.04.016.

Related content

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial

Indication for treatment and severity of disease in treatment-naive patients with chronic hepatitis B virus infection

Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial

Long-Term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients with Chronic HCV Infection

Hepatitis flare-related decompensation is associated with better outcomes in patients with chronic hepatitis B

Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic HBV Infection: Systematic Review and Meta-analysis

Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy

Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study